Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and Avita Medical (NASDAQ:RCEL – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.
Volatility & Risk
Anteris Technologies Global has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
Earnings & Valuation
This table compares Anteris Technologies Global and Avita Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $2.24 million | 276.46 | -$94.14 million | ($1.95) | -3.26 |
| Avita Medical | $71.61 million | 5.76 | -$48.59 million | ($1.44) | -9.31 |
Avita Medical has higher revenue and earnings than Anteris Technologies Global. Avita Medical is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Anteris Technologies Global and Avita Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -4,619.27% | -77.69% | -67.99% |
| Avita Medical | -56.96% | N/A | -78.53% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Anteris Technologies Global and Avita Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 1 | 3 | 0 | 2.40 |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
Anteris Technologies Global presently has a consensus price target of $14.00, indicating a potential upside of 120.13%. Avita Medical has a consensus price target of $12.20, indicating a potential downside of 9.02%. Given Anteris Technologies Global’s higher probable upside, equities research analysts clearly believe Anteris Technologies Global is more favorable than Avita Medical.
Insider and Institutional Ownership
27.7% of Avita Medical shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 2.2% of Avita Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Avita Medical beats Anteris Technologies Global on 9 of the 14 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
